ENIMMUNE CORP. is a Taiwan-based biotechnology new drug company mainly engaged in the development, produce and distribution of new drugs. The Company's new drug products include biological agents, monoclonal antibodies, vaccines, and small molecule drugs. The Company mainly conducts drug testing business, biotechnology service business, international trade business, western medicine wholesale and retail business. The product is Tuberculin PPD.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-21	NT$15.95	-0.93%	14,304
26-10-20	NT$16.10	-1.23%	26,316
26-10-19	NT$16.30	-0.31%	54,499
26-10-16	NT$16.35	+0.93%	119,953
26-10-15	NT$16.20	-0.31%	45,902

End-of-day quote Taipei Exchange

More quotes

End-of-day quote Taipei Exchange 2026-10-21			5-day change	1st Jan Change
15.95 ^TWD	-0.93%		-1.85%	-22.57%

10-15	Duopharma Biotech Berhad Signs Five-Year Exclusive Distribution Agreement with Enimmune Corporation in Malaysia	CI
08-12	Enimmune Corporation Reports Earnings Results for the Half Year Ended June 30, 2026	CI

Market Cap	1.15B 35.46M 31.6M 29.26M 26.48M 49.89M 3.35B 50.48M 351M 138M 1.76B 133M 130M 5.61B	P/E 2024	-11.3x	P/E 2025	-9.04x
Enterprise Value	1.1B 33.78M 30.1M 27.87M 25.22M 47.52M 3.19B 48.08M 334M 131M 1.68B 127M 124M 5.34B	EV / Sales 2024	35.4x	EV / Sales 2025	29.7x
Free-Float	28.72%	Yield 2024 *	-	Yield 2025	-

10-15	Duopharma Biotech Berhad Signs Five-Year Exclusive Distribution Agreement with Enimmune Corporation in Malaysia	CI
08-12	Enimmune Corporation Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-08	Enimmune Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
25-08-13	Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-04-17	Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-08-13	Enimmune corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-03-13	Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
23-08-11	Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2023	CI
23-04-21	Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2022	CI
22-08-15	Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2022	CI
22-04-26	Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2021	CI
21-08-13	Enimmune Corporation Reports Earnings Results for the Half Year Ended June 30, 2021	CI
21-04-22	Enimmune Corporation Reports Earnings Results for the Full Year Ended December 31, 2020	CI

1 day	-0.93%
1 week	-1.85%
Current month	-1.24%
1 month	-3.63%
3 months	-2.15%
6 months	-17.57%
Current year	-22.57%

Enimmune corporation Stock

Stocks

6564

TW0006564008

Biotechnology & Medical Research

Valuation: Enimmune corporation

Chart: Enimmune corporation

Latest news: Enimmune corporation

Quotes and Performance

Price Extremes

Managers and Directors: Enimmune corporation

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

1 week	15.95	16.85
1 month	15.4	17.05
Current year	14.9	22.15
1 year	14.9	23.9
3 years	14.65	49.3
5 years	14.65	75.3
10 years	14.49	125

Manager	Title	Age	Since
Che Wei Chang CEO	Chief Executive Officer	-	2019-01-06
Ching Fen Yang CTO	Chief Tech/Sci/R&D Officer	-	2014-07-20
Hung Tun Chen AUD	Comptroller/Controller/Auditor	-	-

Director	Title	Age	Since
Chung Cheng Liu CHM	Chairman	-	2019-01-06
Fei Pan BRD	Director/Board Member	-	2014-01-01
Chin Yi Chiu BRD	Director/Board Member	-	2015-05-18

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENIMMUNE CORPORATION	-0.93%	-1.85%	-23.87%	-56.18%	35.56M
WUXI APPTEC CO., LTD.	-0.21%	-4.43%	+44.40%	+74.13%	66.34B
LONZA GROUP AG	-0.22%	+6.53%	+11.68%	+87.32%	52.92B
ARGENX SE	+0.82%	+5.41%	+8.05%	+73.53%	54.82B
IQVIA HOLDINGS INC.	+3.28%	+5.58%	+26.51%	+50.05%	44.09B
BEONE MEDICINES AG	+0.51%	+9.95%	+22.40%	+133.92%	43.72B
REVOLUTION MEDICINES, INC.	-1.15%	+0.39%	+263.21%	+594.60%	42.13B
CELLTRION, INC.	+0.10%	+9.90%	+16.11%	+59.33%	33.96B
WUXI BIOLOGICS (CAYMAN) INC.	-0.77%	+1.03%	+37.19%	+6.48%	26.17B
GENMAB A/S	+0.69%	+5.60%	+36.60%	+26.94%	23.37B
Average	+0.24%	+4.11%	+44.23%	+105.01%	38.75B
Weighted average by Cap.	+0.37%	+4.54%	+50.62%	+127.71%

	2024	2025
Net sales	39.92M 1.23M 1.1M 1.02M 919K 1.73M 116M 1.75M 12.17M 4.78M 61.03M 4.62M 4.52M 194M	48.19M 1.49M 1.32M 1.23M 1.11M 2.09M 140M 2.11M 14.69M 5.77M 73.69M 5.57M 5.46M 235M
Net income	-158M -4.86M -4.33M -4.01M -3.63M -6.83M -458M -6.91M -48.04M -18.85M -241M -18.22M -17.84M -768M	-164M -5.07M -4.51M -4.18M -3.78M -7.13M -478M -7.21M -50.11M -19.66M -251M -19M -18.61M -801M
Net Debt	-382M -11.77M -10.49M -9.71M -8.79M -16.56M -1.11B -16.76M -116M -45.7M -584M -44.17M -43.25M -1.86B	-54.59M -1.68M -1.5M -1.39M -1.26M -2.37M -159M -2.4M -16.65M -6.53M -83.47M -6.31M -6.18M -266M